2026-01-22 - Analysis Report
**Company Overview**: Eli Lilly is a pharmaceutical company that researches, develops, and manufactures a wide range of pharmaceutical and vaccine products for various diseases.

**Return Rate Comparison**
* Cumulative Return of Review Stock: 281.03%
* Cumulative Return of Comparison Stock (S&P 500, VOO): 91.55%
* Divergence: 173.60 (max: 233.30, min: -31.10, current: 173.60, relative divergence: 77.40%)

The cumulative return of Eli Lilly stock significantly outperforms the S&P 500 index, indicating a higher growth rate.

**Alpha, Beta Analysis**
| Year | CAGR | MDD | Alpha | Beta | Cap(B) |
|------|------|------|-------|------|-------|
| 2016-2018 | 37.0% | 14.3% | 32.0% | 0.7 | 103.7B |
| 2017-2019 | 36.0% | 14.7% | 19.0% | 0.7 | 117.8B |
| 2018-2020 | 30.0% | 20.9% | 9.0% | 0.7 | 151.4B |
| 2019-2021 | 49.0% | 20.9% | 5.0% | 0.7 | 247.6B |
| 2020-2022 | 59.0% | 20.9% | 60.0% | 0.7 | 328.0B |
| 2021-2023 | 116.0% | 18.0% | 115.0% | 0.5 | 522.6B |
| 2022-2024 | 123.0% | 27.0% | 104.0% | 0.6 | 692.1B |
| 2023-2025 | 183.0% | 29.9% | 121.0% | 0.7 | 963.4B |

The company shows a high alpha (growth rate) and beta (systematic risk) across various periods, indicating high volatility and growth potential.

**Recent Stock Price Fluctuations**
* Close: $1,078.52
* Last-Market: $1078.52 (3.58% change)
* 5-day SMA: $1,052.89
* 20-day SMA: $1,070.07
* 60-day SMA: $1,017.17

The current stock price is above the 5-day and 20-day SMA, indicating a short-term upward trend.

**RSI, PPO, and Delta_Previous_Relative_Divergence Analysis**
* Market Risk Indicator (MRI): 0.80 (High Investment Recommended)
* RSI: 49.77
* PPO: -0.50
* Hybrid Signal: Buy (Cash 0%)
Risk Level: Medium (MRI 0.80)
* Recent (20 days) relative divergence change: -3.10 (-) worsening
* 7-day Rank change: 2 (+) rank up
* 7-day Dynamic Expected Return change: -1.20 (-) worsening

The current market risk indicator is slightly above the medium investment threshold, indicating a relatively low risk. The RSI is around 50, indicating a neutral sentiment. The PPO is slightly below 0, indicating a short-term bearish sentiment.

**Recent News & Significant Events**
1. "Why Eli Lilly (LLY) Stock Is Up Today" (Yahoo Finance)
2. "3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026" (MarketBeat)
3. "Abivax CEO Dismisses Rumors of Eli Lilly (LLY) Takeover as ‘Noise’" (TipRanks)
4. “Eli Lilly: Buy Ahead Of Its Earnings Day (Preview)" (Seeking Alpha)
5. "Prediction: 2026 Will Be the Year of Eli Lilly" (The Motley Fool)
6. "Which Pharma Stock Stands Taller Right Now: LLY or PFE?" (Yahoo Finance)

These news headlines suggest that Eli Lilly is expected to perform well in 2026 and may be a good investment opportunity.

**Analyst Opinions**
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.70 (~Buy)
- Opinions: 28
- Target Price (avg/high/low): 1110.71 / 1500.00 / 770.00

Analysts have a slightly bearish consensus, but the target price is higher than the current stock price.

**Recent Earnings Analysis**
| Date | EPS | Revenue |
|-----|-----|---------|
| 2025-10-30 | 6.22 | $17.60B |
| 2025-08-07 | 6.3 | $15.56B |
| 2025-05-01 | 3.07 | $12.73B |
| 2024-10-30 | 1.08 | $11.44B |
| 2025-10-30 | 1.08 | $11.44B |

The company's earnings per share (EPS) have been increasing over the past year, indicating a growing profitability.

**Revenue and Profitability Analysis**
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $17.60B | 82.91% |
| 2025-06-30 | $15.56B | 84.27% |
| 2025-03-31 | $12.73B | 82.53% |
| 2024-12-31 | $13.53B | 82.24% |
| 2024-09-30 | $11.44B | 81.02% |

The company's revenue and profit margin have been increasing consistently over the past year, indicating a growing profitability.

**Capital and Profitability Analysis**
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $23.79B | 23.46% |
| 2025-06-30 | $18.27B | 30.98% |
| 2025-03-31 | $15.76B | 17.50% |
| 2024-12-31 | $14.19B | 31.07% |
| 2024-09-30 | $14.24B | 6.81% |

The company's equity and return on equity (ROE) have been increasing over the past year, indicating a growing capital base and profitability.

**Comprehensive Analysis**
Overall, Eli Lilly has shown a high growth rate and profitability over the past year, but the recent decline in stock price indicates some volatility. The analysts have a slightly bearish consensus, but the target price is higher than the current stock price. The company's financials and profitability analysis indicate a growing capital base and profitability.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.